Cibus, Inc. (CBUS) Fair Value 2026

CBUS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (55/100)

Quick Summary — As of 2026-08-27, Cibus, Inc. (CBUS) trades at $1.67. QOC: 5.2/10. Value Trap Risk: 55/100 (WARN). 1/13 models active.

Key Facts

Ticker
CBUS
Price
$1.67
Quality Score
5.2/10
Value Trap Risk
55/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +130.8% upside with 31% confidence
Risk: Value Trap score of 55 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CBUS?

1 Intrinsic Value Models vs. Current Price ($1.67)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $3.85 +130.8%

All Models Active

All 1 models are displayed above.

What Is Cibus, Inc. (CBUS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cibus, Inc.'s intrinsic value is estimated at a median fair value of $3.85. At a current market price of $1.67, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +130.8%.

What Do the Models Say About CBUS?

1 of 13 models are currently active for CBUS. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does CBUS Rank in Biotechnology?

Among 620 Biotechnology stocks, CBUS ranks #264 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Cibus, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CBUS a Value Trap?

CirclFi's Value Trap algorithm assigns CBUS a score of 55/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Cibus, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Cibus, Inc. is rated at 5.2/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CBUS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CBUS's 1 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cibus, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CRBUCaribou Biosciences, Inc.QOC 5.2MLECMoolec Science SAQOC 5.2AVIRAtea Pharmaceuticals, Inc.QOC 5.2NKTXNkarta, Inc.QOC 5.2VCNXVaccinex, Inc.QOC 5.2ALXOALX Oncology Holdings Inc.QOC 5.2NTHINeOnc Technologies Holdings, Inc.QOC 4.6KARDKardigan, Inc.QOC 3.5CTMXCytomX Therapeutics, Inc.QOC 6.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CRBU · MLEC · AVIR · NKTX · VCNX · ALXO · NTHI · KARD · CTMX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CBUS?

6 companies across all industries closest to CBUS’s Quality of Company score of 5.2/10.

GRHIGold Rock Holdings, Inc.QOC 5.2ELUTElutia Inc.QOC 5.2LEELee Enterprises, IncorporatedQOC 5.2CMTGClaros Mortgage Trust, Inc.QOC 5.2CTSOCytosorbents CorporationQOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GRHI · ELUT · LEE · CMTG · CTSO · NVDA

Where Does CBUS Sit in CirclFi's Biotechnology Rankings?

CBUS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Cibus, Inc.’s Valuation?

What is Cibus, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Cibus, Inc. (CBUS). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CBUS overvalued or undervalued right now?

At $1.67, 1 of 1 active models suggest CBUS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Cibus, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for CBUS?

Cibus, Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CBUS?

CirclFi analyzes CBUS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CBUS a value trap in 2026?

Cibus, Inc.'s Value Trap score is 55/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Cibus, Inc. (CBUS) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/CBUS/ · Methodology
Primary sources for this CBUS valuation
  • Financial statements: Cibus, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001705843) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CBUS as of ; valuations recomputed .